As the hunt for skilled employees in China intensifies, pharmaceutical group Sanofi is using artificial intelligence to identify the most promising and loyal applicants.
“We are facing a very fierce talent war, not just from multinationals but from a lot of Chinese companies that want to expand,” says Iris Zhou, head of talent acquisition for Asia Pacific.
Sanofi has been using an algorithm for the past two years to assess interns on their potential cultural fit with the organisation. Only then are the shortlisted candidates interviewed by HR staff.
> Read the full article on the Financial Times website
By Andrew Jack
Source: Financial Times
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).